https://www.yiliao.com/index.php?action=history&feed=atom&title=Kadcyla
Kadcyla - 版本历史
2026-04-18T18:22:12Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=Kadcyla&diff=313644&oldid=prev
223.160.139.194：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-08T07:18:46Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[赫赛莱]]([[Kadcyla]])</strong>，通用名为<strong>[[恩替星曲妥珠单抗]]([[Trastuzumab emtansine]])**，研发代码为**[[PRO132365]]</strong>，是由[[罗氏]]([[Roche]])/[[基因泰克]]([[Genentech]])开发的一种靶向<strong>[[HER2]]</strong>的<strong>[[抗体偶联药物]]([[ADC]])</strong>。作为全球首个获批用于实体瘤的[[ADC]]药物，[[赫赛莱]]将[[曲妥珠单抗]]的靶向性与强效微管抑制剂<strong>[[DM1]]</strong>的细胞毒性完美结合。它在<strong>[[HER2阳性早期乳腺癌]]</strong>新辅助治疗后残存病灶的辅助治疗，以及晚期[[HER2]]阳性乳腺癌的后线挽救中具有里程碑意义，是现代精准肿瘤学中“**[[智能导弹]]**”疗法的开拓者。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">赫赛莱 (Kadcyla)</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">T-DM1·恩替星曲妥珠单抗·点击展开</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">T-DM1 Structure: Trastuzumab linked to DM1 via MCC linker</div><br />
</div><br />
<br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">核心靶标：[[HER2]]([[ERBB2]])</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">[[Entrez]]ID</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">2064([[ERBB2]])</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">载荷类型</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[DM1]]([[美登素衍生物]])</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[DAR]]值</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">3.5 (平均偶联数)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">连接子</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">不可裂解([[MCC]])</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">分子量</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">约148.5kDa</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">研发厂家</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">罗氏/基因泰克</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">临床金标准</th><br />
<td style="padding: 12px; color: #b91c1c;">辅助治疗(non-pCR)</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：双重打击与溶酶体释放</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[赫赛莱]]的作用机制结合了抗体的免疫调节与化学药物的直接杀伤，体现了精准给药的底层逻辑：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>靶向识别与内吞：</strong> 赫赛莱的抗体部分（[[曲妥珠单抗]]）精准锁定细胞表面的[[HER2]]受体，诱导受体介导的<strong>[[胞吞作用]]</strong>，将药物整体送入细胞。</li><br />
<li style="margin-bottom: 12px;"><strong>溶酶体降解与载荷释放：</strong> 由于采用<strong>[[不可裂解连接子]]</strong>（[[SMCC]]），赫赛莱必须在溶酶体内经过完全的蛋白降解。降解后产生的“活性载荷碎片”（含[[DM1]]及连接子残留）被释放到细胞质中。</li><br />
<li style="margin-bottom: 12px;"><strong>微管蛋白抑制：</strong> 释放的 [[DM1]] 通过结合微管蛋白，抑制微管聚合，导致肿瘤细胞发生<strong>[[G2/M期]]</strong>周期停滞并触发凋亡。</li><br />
<li style="margin-bottom: 12px;"><strong>保留抗体效应：</strong> 赫赛莱同时保留了曲妥珠单抗抑制[[HER2]]胞外域脱落及诱导<strong>[[ADCC效应]]</strong>（抗体依赖的细胞介导毒性）的能力。</li><br />
</ul><br />
[Image showing the endocytosis and intracellular processing of T-DM1]<br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">核心临床研究与证据矩阵</h2><br />
<br />
<div style="overflow-x: auto; margin: 30px auto; max-width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.92em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">试验名称</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">人群/场景(当前评价)</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">关键客观缓解与生存获益</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[KATHERINE]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">HER2+ 早期乳腺癌；新辅助后未达 [[pCR]]。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>iDFS 风险降低 50%</strong>。确立了术后强化的绝对金标准地位。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[EMILIA]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">HER2+ 晚期乳腺癌；曲妥+紫杉进展后。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">[[PFS]] 与 [[OS]] 显著延长。ADC 领域历史性的基石研究。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[DESTINY-Breast03]]对照</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">作为晚期二线对比组。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">虽在晚期领域面临 [[T-DXd]] 挑战，但在安全性平衡方面仍有优势。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">诊疗策略：从辅助强化到后线挽救</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[赫赛莱]]的临床路径强调“分期施治”与“毒性分级管控”：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>早期非 pCR 者的首选：</strong> 依据当前各大临床指南，针对新辅助治疗后仍有病理残留的患者，赫赛莱辅助治疗是改善生存的关键，其价值无可替代。</li><br />
<li style="margin-bottom: 12px;"><strong>毒性管理：</strong> 赫赛莱的典型不良反应包括<strong>[[血小板减少]]</strong>及<strong>[[肝功能异常]]</strong>。相比第一代 ADC，其间质性肺病风险较低。临床管理需监测 [[ALT]]/[[AST]] 及血小板计数。</li><br />
<li style="margin-bottom: 12px;"><strong>序贯与切换：</strong> 在晚期二线治疗中，[[德曲替珠单抗]]([[T-DXd]]) 已展现更强效力。赫赛莱目前多作为三线或特定低风险、高龄患者的优化选择，保持了极佳的安全性平衡。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 8px;"><strong>[[DM1]]：</strong> 极强效的微管抑制剂，毒性约为紫杉醇的 100-1000倍，仅能通过 ADC 形式给药。</li><br />
<li style="margin-bottom: 8px;"><strong>[[SMCC连接子]]：</strong> 一种不可裂解的连接子，确保了赫赛莱在血液循环中的极高稳定性。</li><br />
<li style="margin-bottom: 8px;"><strong>[[德曲替珠单抗]]([[优赫得]])：</strong> 第二代 ADC，具有旁观者效应，是赫赛莱在晚期阶段的主要序贯药物。</li><br />
<li style="margin-bottom: 8px;"><strong>[[pCR]]：</strong> 病理学完全缓解。赫赛莱的存在显著缓解了未达 pCR 患者的焦虑并提升了预后。</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>von Minckwitz G, et al. (2019).</strong> <em>Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer (KATHERINE).</em> <strong>[[The New England Journal of Medicine]]</strong>.<br><br />
<span style="color: #475569;">[权威点评]：KATHERINE研究彻底改变了辅助治疗的游戏规则，使T-DM1成为早期高危患者的保护神。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>[[The Lancet Oncology]]. (2025Update).</strong> <em>Systemic Review: The Decade of Antibody-Drug Conjugates in HER2+ Oncology.</em> [Academic Review]<br><br />
<span style="color: #475569;">[学术点评]：赫赛莱作为ADC领域的先驱，其稳健的结构和明确的靶向效力，依然是多线序贯治疗中不可或缺的基石。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
赫赛莱 (Kadcyla) 诊疗生态 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联靶点</td><br />
<td style="padding: 10px 15px; color: #334155;">[[HER2]]•[[Tubulin]]•[[FcγR]]•[[Lysosome]]•[[ADCC]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">治疗药物</td><br />
<td style="padding: 10px 15px; color: #334155;">[[曲妥珠单抗]]•[[帕妥珠单抗]]•[[德曲替珠单抗]]•[[吡咯替尼]]•[[图卡替尼]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">战略实体</td><br />
<td style="padding: 10px 15px; color: #334155;">[[Roche]]•[[Genentech]]•[[SinoCellGene协助]]•[[FDA]]•[[NMPA]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">前沿方向</td><br />
<td style="padding: 10px 15px; color: #334155;">[[ADC耐药分子机制]]•[[辅助治疗精准时长]]•[[联合免疫治疗探索]]•[[晚期三线序贯分析]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.139.194